2023
Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active nonsegmental vitiligo and either a lighter or darker Fitzpatrick skin type: results from a phase 2b, randomized, dose-ranging study with an extension period
Peeva E, Yamaguchi Y, King B, Han G, Cox L, Banerjee A, Picardo M, Bae J, Sloan A, Sinclair R, Ezzedine K. Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active nonsegmental vitiligo and either a lighter or darker Fitzpatrick skin type: results from a phase 2b, randomized, dose-ranging study with an extension period. British Journal Of Dermatology 2023, 188: ljac106.004. DOI: 10.1093/bjd/ljac106.004.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsDose-ranging periodNonsegmental vitiligoLoading doseFitzpatrick skin typeIncidence of treatment-emergent adverse eventsFacial Vitiligo Area Scoring IndexTreatment-emergent adverse event incidenceLow dosesDarker Fitzpatrick skin typesVitiligo Area Scoring IndexDaily loading dosesRandomized to placeboDose-ranging studyPhase 2b studyPhase 2b trialLow-dose groupCytokine IL-15Skin typePlateau of effectivenessSafety endpointsIL-15IFN-gAdverse eventsVitiligo patients
2022
33304 Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active nonsegmental vitiligo and either a lighter or darker Fitzpatrick skin type: Results from a phase 2b, randomized, dose-ranging study with an extension period
Peeva E, Yamaguchi Y, King B. 33304 Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active nonsegmental vitiligo and either a lighter or darker Fitzpatrick skin type: Results from a phase 2b, randomized, dose-ranging study with an extension period. Journal Of The American Academy Of Dermatology 2022, 87: ab105. DOI: 10.1016/j.jaad.2022.06.453.Peer-Reviewed Original ResearchDose-ranging studyDarker Fitzpatrick skin typesFitzpatrick skin typeNonsegmental vitiligoPhase 2bSkin typeExtension periodPatientsVitiligo